欧必亭(Navoban)在乳腺癌化疗中止吐疗效的观察及对比

Anti－Emetic Effect of Navoban on Prevention of Emesis Induced by Chemotherapy of Breast Cancer

目的：观察欧必亭在乳腺癌化疗过程中的作用，并与恩丹西酮，维生素B_(6＋)氟美松进行对比，观察其止吐疗效和副作用。方法：120例采用CMF（环磷酰胺，氨甲蝶呤，氟脲嘧啶）化疗的乳腺癌患者，采用随机平行对照方法，分别给予欧必亭5mg静脉注射，或恩丹西酮8mg静脉注射，或维生素B_6 200_(mg＋)氟美松5mg静脉注射。结果：欧必亭止吐有效率达98．5％，完全控制率达95．0％，对控制恶心有效率达93．5％，完全控制率达80．0％。而恩丹西酮与之相比效果不佳（P＜0．05＝，维生素B_(6＋)氟美松效果较差（P＜0．05）。并且欧必亭的副作用很轻微。结论：欧必亭对乳腺癌化疗患者具有很好的止吐、止恶心作用。

Objective: To evaluate the efficacy and toxicity of Navoban (Tropisetron) for prevention of nausea and vomiting induced by combination chemotherapy of breast cancer, and it was compared with those of Ondansetron and Vitamin B_(6＋) DXM． Methods: One hundred and twenty patients were enrolled by parallel contrast method and Navoban 5mg iv； Ondansetron 8mg iv； Vitamin B_(6＋)DXM 5mg iv were given before combination chemotherapy． Results: The complete anti－emetic response rate of the Navoban group was 98．5％ and the overall response rate was 95％； the complete and overall response rates to nausea were 93．5％ and 80％ respectively． After comparison, the effect of Navoban group was far superior to that of Ondansetron or Vitamin B_(6＋) DXM group． Conclusion: Navoban has a good effect for prevention of emesis induce by combination chemotherapy of breast cancer．